Marinus Pharmaceuticals, Inc (NASDAQ:MRNS) Given Average Recommendation of Moderate Buy by Brokerages theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Royal Bank of Canada reaffirmed their sector perform rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a research note released on Monday morning, Marketbeat.com reports. Royal Bank of Canada currently has a $3.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $24.00. Other equities analysts also […]
StockNews.com downgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) from a hold rating to a sell rating in a research note issued to investors on Wednesday. Several other brokerages also recently weighed in on MRNS. Truist Financial cut their price target on Marinus Pharmaceuticals from $32.00 to $25.00 and set a buy rating on […]
Marinus Pharmaceuticals, Inc (NASDAQ:MRNS) Receives Consensus Rating of Moderate Buy from Analysts themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Suvretta Capital Management LLC reduced its stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Free Report) by 16.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,057,611 shares of the biopharmaceutical company’s stock after selling 773,650 shares during the quarter. Marinus Pharmaceuticals […]